A large review of studies looked at whether certain antibodies, called anti-IFN-I antibodies, are linked to severe COVID-19. These antibodies attack the body's own immune system, specifically proteins that help fight viruses early on. The review combined data from many studies involving over 11,000 people infected with the virus that causes COVID-19.
The results showed that about 8% of all COVID-19 patients had these antibodies. However, they were much more common in people with severe or critical illness. Among those with severe disease, about 11% had the antibodies, and among those who died, about 15% had them. This suggests that these antibodies may make it harder for the body to fight off the virus, leading to worse outcomes.
The review also found a strong link between having these antibodies and the severity of the disease. People with these antibodies were much more likely to have severe or critical COVID-19 compared to those without them. This link was consistent across different regions of the world, including Europe, North America, South America, Asia, and the Middle East.
It's important to note that this review does not prove that these antibodies cause severe COVID-19. It only shows an association. However, the findings suggest that testing for these antibodies could help identify people at higher risk. The researchers estimate that these antibodies might account for a significant number of COVID-19 deaths worldwide, but this is a rough estimate.
Overall, this review highlights the importance of the immune system's early response in fighting COVID-19. Understanding how these antibodies work could lead to better treatments or preventive strategies for those at risk.
